The effect of TIPS operation on peripheral blood T cell subsets of perioperative patients with portal hypertension

Abstract

Abstract: Objective To explore the effect of transjugular intrahepatic portosystemic shunt (TIPS) on peripheral blood T cell subsets of perioperative patients with portal hypertension. Methods A retrospective analysis was conducted on patients with portal hypertension who underwent TIPS from May 2023 to August 2023. The changes in peripheral blood T cell subsets before and after TIPS was analyzed. Results The study included a total of 22 patients, with a preoperative pressure gradient (PPG) of 23.64 ± 6.8 mmHg and a postoperative PPG of 9.27 ± 4.7 mmHg (P<0.05); Preoperative blood ammonia levels were 74.38±31.30 μg/dL, and postoperative blood ammonia levels were 88.43+42.20 μg/dL. There was no statistically significant difference in postoperative blood ammonia levels. The changes in postoperative lymphocytes, CD8⁺ T cell/lymphocyte ratio, and T cell/lymphocyte ratio showed statistical differences (P<0.05). Postoperative follow-up revealed that 2 patients died and 6 (27%) had obvious hepatic encephalopathy. Through comparison, it was found that patients with hepatic encephalopathy had a significantly reduced number of lymphocytes after surgery compared to patients without hepatic encephalopathy (431.9±493.8 vs. 65.5±247.2, P=0.031). Conclusion The T cell subpopulations in patients after TIPS operation may change and this may be associated with the occurrence of hepatic encephalopathy in these patients.

Key words: Transjugular intrahepatic portosystemic shunt, T cell subpopulations, Hepatic encephalopathy, Portal hypertension

JING Chang-you, ZHU Tong, GAO Wen-feng, ZHANG Yong-hong, LI Jian-jun. The effect of TIPS operation on peripheral blood T cell subsets of perioperative patients with portal hypertension[J]. Chinese Hepatolgy, 2025, 30(6): 781-783.

References

[1] Boike J R, Thornburg B G, Asrani S K, et al. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. Clin Gastroenterol Hepatol,2022,20(8):1636-1662.e36.
[2] Queck A, Rueschenbaum S, Kubesch A, et al. The portal vein as a distinct immunological compartment :a comprehensive immune phenotyping study[J]. Hum Immunol,2018,79(10):716-723.
[3] 原子英,郭津生. 肝硬化相关免疫功能障碍的特点及其临床相关性[J]. 中华肝脏病杂志, 2016,24(10):4.
[4] Benten D, Schulze zur Wiesch J, Sydow K, et al. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS)[J]. BMC Gastroenterol,2011,11(1):107.
[5] Nkongolo S, Mahamed D, Kuipery A, et al. Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8⁺ T cells[J]. J Clin Invest,2023,133(1):e158903.
[6] Thabut D, Bouzbib C, Meunier L, et al. Diagnosis and management of hepatic encephalopathy: the French recommendations[J]. Liver Int,2023,43(4):750-762.
[7] Lin X, Gao F, Wu X, et al. Efficacy of albumin-bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol,2021,33(6):862-871.
[8] Wang L J, Yao X, Qi Q, et al. Prevention and treatment of hepatic encephalopathy during the perioperative period of transjugular intrahepatic portosystemic shunt[J]. World J Gastrointest Surg,2023,15(8):1564-1573.
[9] Garcovich M, Zocco M A, Roccarina D, et al. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota[J]. World J Gastroenterol, 2012,18(46):6693-6700.
[10] Shawcross, Debbie L. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy?[J]. Expert Review of Gastroenterology & Hepatology,2015,9(5):539-542.
[11] Mangas-Losada A, García-García R, Urios A, et al. Minimal hepatic encephalopathy is associated with expansion and activation of CD4⁺CD28^-, Th22 and Tfh and B lymphocytes[J]. Rep,2017,7(1):6683.

[1]	LIU Jia, LIU Yan, CHEN Jin. An analysis on the risk factors of portal vein thrombosis in cirrhotic patients with portal hypertension and hypersplenism after laparoscopic splenectomy [J]. Chinese Hepatolgy, 2025, 30(5): 604-608.
[2]	MI Lan, WANG Yan-chuan, ZHOU Li-qiong. Effects of xingnaojing combined with naloxone on blood ammonia level and cognitive impairment in patients with hepatitis B cirrhosis complicated with hepatic encephalopathy [J]. Chinese Hepatolgy, 2025, 30(4): 525-528.
[3]	WANG Ye-long, WANG Yang, SHEN Hua, YU Hai-wen, LI You. Clinical features and influencing factors of pancreatic portal hypertension [J]. Chinese Hepatolgy, 2025, 30(4): 552-556.
[4]	MA Ying-hui, LIN He, WANG Lei, ZHANG Yu, ZHAO Ya-li. The application and influencing factors of endoscopic ultrasound in measuring portal vein pressure gradient in patients with liver cirrhosis and portal hypertension [J]. Chinese Hepatolgy, 2025, 30(3): 301-304.
[5]	HE Yang, YANG Bo-shuai, HOU Yi-bin, ZHOU Su, YUAN Min. A preliminary exploration for the diagnosis and treatment of pseudocirrhosis [J]. Chinese Hepatolgy, 2025, 30(3): 305-309.
[6]	XIE Xiao-zhen, YANG Xiao-liang, LIU Wen-feng. Dynamic changes in regional neural activity and its relationship with clinical behavior of patients with mild hepatic encephalopathy using resting state functional magnetic resonance imaging [J]. Chinese Hepatolgy, 2025, 30(3): 326-329.
[7]	MA Zhi-gang, LIU Li-li, WANG Xu, FENG Peng-li, YANG Fan, YANG Yong-bin. A prediction model of mortality risk after interventional operation on cirrhotic portal hypertensive patients complicated with esophagogastric varices rupture and hemorrhage [J]. Chinese Hepatolgy, 2025, 30(2): 183-186.
[8]	DU Xin-yang, SHI Ke. Evaluation of hepatic blood perfusion parameters using spiral CT after transjugular intrahepatic portosystemic shunt in patients with hepatitis B cirrhosis and portal hypertension [J]. Chinese Hepatolgy, 2025, 30(2): 207-210.
[9]	DENG Wen-jia, WANG Lei, WANG Hao-ran, ZHAO Ge. A clinical research on the risk factors and the development of diagnostic model for hepatic encephalopathy [J]. Chinese Hepatolgy, 2024, 29(9): 1085-1090.
[10]	DANBA Yu-zhen, WANG Wan-ting. CT perfusion imaging study of esophageal variceal collateral circulation in patients with hepatitis B cirrhosis portal hypertension [J]. Chinese Hepatolgy, 2024, 29(9): 1096-1099.
[11]	YAN Yu-feng, YUAN Min, HE Yang, TU Chuan-tao, SHI Yu-xin, WANG Lin, WANG Yue, FU Qing-chun. Construction and application of a digital management platform for multidisciplinary consultation and management of portal hypertension [J]. Chinese Hepatolgy, 2024, 29(7): 802-807.
[12]	WANG Li-hui, LIU Shuang-ping, LU Qiu-yan, SHEN Pei-gen, XU Cheng-run. Factors and prognostic evaluation of covert hepatic encephalopathy in patients with hepatitis B-related cirrhosis [J]. Chinese Hepatolgy, 2024, 29(7): 817-820.
[13]	LI Yan, CHEN Qian, ZHOU Shu-ping, LIU Xin-kuang, XU Bin. Efficacy of microecological agents combined with ornithine aspartate in treatment of patients with subclinical hepatic encephalopathy and its influence on liver function and cognitive function [J]. Chinese Hepatolgy, 2024, 29(7): 821-824.
[14]	MA Zhi-gang, LIU Li-li, WANG Xu, FENG Peng-li, YANG Fan, YANG Yong-bin. The impacts of transjugular intrahepatic portosystemic shunt on the portal vein diameter and long-term outcome of liver cirrhotic patients with portal hypertension [J]. Chinese Hepatolgy, 2024, 29(5): 516-520.
[15]	WENG Cheng-zhao, WANG Chao, ZHANG Jun, LIN Si-hui, LIN Chong, CHEN Shi-yao, JIANG Wei. The clinical characteristics of patients with spontaneous portalsystemic shunt and isolated gastric variceal bleeding [J]. Chinese Hepatolgy, 2024, 29(2): 157-161.